If you or someone you know is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is critical for early detection and informed decision-making. Decades of pharmacovigilance have established that PML, though rare, requires careful monitoring through clinical checks and MRI surveillance. This page provides a concise checklist of facts to review with your healthcare provider.
Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for moderate-to-severe active Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri highlighting this risk, emphasizing that healthcare professionals must monitor patients for any new signs or symptoms suggestive of PML and withhold dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors increase the likelihood of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected therapeutic benefit when initiating or continuing therapy. Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The clinical presentation of PML can be variable, often including progressive neurological deficits such as weakness, cognitive decline, visual disturbances, or coordination problems. Diagnosis typically relies on brain MRI and detection of JCV DNA in cerebrospinal fluid. Early recognition is critical, as prompt withdrawal of Tysabri may improve outcomes. However, PML has been reported even after discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of stopping treatment. Therefore, monitoring for new signs or symptoms should continue for at least six months following discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Prognosis for Tysabri-associated PML is generally poor, with the boxed warning stating that the infection "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Treatment for severe PML after Tysabri exposure focuses on supportive care and immune reconstitution. The primary intervention is discontinuation of Tysabri to allow restoration of immune surveillance. In some cases, plasma exchange or immunoadsorption may be used to accelerate clearance of natalizumab from the bloodstream, potentially hastening immune recovery. However, immune reconstitution inflammatory syndrome (IRIS) can occur as the immune system recovers, leading to paradoxical worsening of neurological symptoms. Management of IRIS may involve corticosteroids, but this must be carefully balanced against the risk of further immunosuppression.
The timeline between Tysabri exposure and documented PML harm varies. PML risk increases with cumulative treatment duration, particularly after two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Cases have been reported both during active treatment and after discontinuation, underscoring the need for prolonged vigilance. The FDA boxed warning mandates that Tysabri dosing be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, the prognosis remains guarded, and many affected patients experience significant long-term disability or death. Adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning, the TOUCH Prescribing Program, and ongoing monitoring requirements. The prescribing information explicitly states that Tysabri increases PML risk and that patients should be monitored for new neurological symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For multiple sclerosis patients, an MRI scan should be obtained before initiating therapy to help differentiate subsequent MS symptoms from PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In Crohn's disease patients, a baseline brain MRI may also be helpful, though brain lesions at baseline that could cause diagnostic difficulty are uncommon (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
In summary, Tysabri-associated PML carries a grave prognosis, with treatment centered on drug discontinuation and supportive care. The FDA has implemented robust warning and monitoring protocols, but the infection remains a serious adverse event with high morbidity and mortality. Clinicians must maintain a high index of suspicion for PML in any Tysabri-treated patient presenting with new neurological symptoms, even after treatment cessation.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The prognosis for Tysabri-associated PML is generally poor, with the FDA boxed warning stating that the infection "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Many affected patients experience significant long-term disability or death despite treatment.
Treatment for severe PML after Tysabri exposure focuses on supportive care and immune reconstitution. The primary intervention is discontinuation of Tysabri to allow restoration of immune surveillance. In some cases, plasma exchange or immunoadsorption may be used to accelerate clearance of natalizumab from the bloodstream. Management of immune reconstitution inflammatory syndrome (IRIS) may involve corticosteroids, but this must be carefully balanced against the risk of further immunosuppression.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.